137 related articles for article (PubMed ID: 18853252)
21. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K
Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283
[TBL] [Abstract][Full Text] [Related]
22. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer.
Gellert GC; Dikmen ZG; Wright WE; Gryaznov S; Shay JW
Breast Cancer Res Treat; 2006 Mar; 96(1):73-81. PubMed ID: 16319992
[TBL] [Abstract][Full Text] [Related]
23. Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer.
Sridhar J; Sfondouris ME; Bratton MR; Nguyen TL; Townley I; Klein Stevens CL; Jones FE
Bioorg Med Chem Lett; 2014 Jan; 24(1):126-31. PubMed ID: 24355130
[TBL] [Abstract][Full Text] [Related]
24. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
26. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
[TBL] [Abstract][Full Text] [Related]
27. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
28. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
29. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
30. Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin.
Liang CH; Shiu LY; Chang LC; Sheu HM; Tsai EM; Kuo KW
Chem Res Toxicol; 2008 Feb; 21(2):393-9. PubMed ID: 18078328
[TBL] [Abstract][Full Text] [Related]
31. Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.
Rowe DL; Ozbay T; Bender LM; Nahta R
Mol Cancer Ther; 2008 Jul; 7(7):1900-8. PubMed ID: 18645000
[TBL] [Abstract][Full Text] [Related]
32. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
33. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
[TBL] [Abstract][Full Text] [Related]
34. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel.
Goldblatt EM; Gentry ER; Fox MJ; Gryaznov SM; Shen C; Herbert BS
Mol Cancer Ther; 2009 Jul; 8(7):2027-35. PubMed ID: 19509275
[TBL] [Abstract][Full Text] [Related]
35. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Scaltriti M; Eichhorn PJ; Cortés J; Prudkin L; Aura C; Jiménez J; Chandarlapaty S; Serra V; Prat A; Ibrahim YH; Guzmán M; Gili M; Rodríguez O; Rodríguez S; Pérez J; Green SR; Mai S; Rosen N; Hudis C; Baselga J
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3761-6. PubMed ID: 21321214
[TBL] [Abstract][Full Text] [Related]
36. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Ozbay T; Durden DL; Liu T; O'Regan RM; Nahta R
Cancer Chemother Pharmacol; 2010 Mar; 65(4):697-706. PubMed ID: 19636556
[TBL] [Abstract][Full Text] [Related]
37. PPM1H is a p27 phosphatase implicated in trastuzumab resistance.
Lee-Hoeflich ST; Pham TQ; Dowbenko D; Munroe X; Lee J; Li L; Zhou W; Haverty PM; Pujara K; Stinson J; Chan SM; Eastham-Anderson J; Pandita A; Seshagiri S; Hoeflich KP; Turashvili G; Gelmon KA; Aparicio SA; Davis DP; Sliwkowski MX; Stern HM
Cancer Discov; 2011 Sep; 1(4):326-37. PubMed ID: 22586611
[TBL] [Abstract][Full Text] [Related]
38. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells.
Carpin LB; Bickford LR; Agollah G; Yu TK; Schiff R; Li Y; Drezek RA
Breast Cancer Res Treat; 2011 Jan; 125(1):27-34. PubMed ID: 20217215
[TBL] [Abstract][Full Text] [Related]
39. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells.
Catania A; Barrajón-Catalán E; Nicolosi S; Cicirata F; Micol V
Breast Cancer Res Treat; 2013 Aug; 141(1):55-65. PubMed ID: 23959397
[TBL] [Abstract][Full Text] [Related]
40. [Effects of single versus combined use of trastuzumab and cantide on breast cancer cells SKBR3 over-expressing HER2].
Zhang F; Yang JL; You JH; Feng F; Ren L; Xie WX; Li ZJ
Zhonghua Yi Xue Za Zhi; 2012 May; 92(20):1384-7. PubMed ID: 22883194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
